NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) and Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability and analyst recommendations.
Profitability
This table compares NRx Pharmaceuticals and Amneal Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NRx Pharmaceuticals | -691.81% | N/A | -63.92% |
| Amneal Pharmaceuticals | 5.05% | -584.46% | 7.78% |
Earnings and Valuation
This table compares NRx Pharmaceuticals and Amneal Pharmaceuticals”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NRx Pharmaceuticals | $1.23 million | 91.53 | -$28.62 million | ($0.55) | -4.73 |
| Amneal Pharmaceuticals | $3.12 billion | 1.96 | $72.06 million | $0.49 | 39.14 |
Amneal Pharmaceuticals has higher revenue and earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and target prices for NRx Pharmaceuticals and Amneal Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NRx Pharmaceuticals | 2 | 0 | 6 | 0 | 2.50 |
| Amneal Pharmaceuticals | 1 | 0 | 9 | 0 | 2.80 |
NRx Pharmaceuticals presently has a consensus target price of $34.50, suggesting a potential upside of 1,226.92%. Amneal Pharmaceuticals has a consensus target price of $21.00, suggesting a potential upside of 9.49%. Given NRx Pharmaceuticals’ higher possible upside, analysts clearly believe NRx Pharmaceuticals is more favorable than Amneal Pharmaceuticals.
Risk and Volatility
NRx Pharmaceuticals has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500.
Institutional & Insider Ownership
4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 6.4% of NRx Pharmaceuticals shares are held by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Amneal Pharmaceuticals beats NRx Pharmaceuticals on 10 of the 14 factors compared between the two stocks.
About NRx Pharmaceuticals
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.jpg){kind=logo}
